AzTrials
AzTrials

TransplantRECOVERYNCT05717842

Simultaneous Prospective Kidney Transplant Assessment in Combined Liver Kidney Candidates

An observational study of Transplant, run by Indiana University at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of the study is to determine how much a persons kidney function recovers after receiving a simultaneous liver kidney transplant. The investigators will be contacting patients with kidney dysfunction with estimated GFR between 25 and 40 (not on dialysis treatment) who are listed to receive a simultaneous… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Transplant
What is being tested?
Nuclear Medicine Scan
Type of treatment
Surgery or procedure
How many people
15 participants
Where
1 siteUnited States
Study dates
8 Dec 2023to Feb 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Individuals who have end stage liver disease (ESLD) and kidney dysfunction, who are not on dialysis and have eGFR >=25 and <=40 ml/min for a duration of at least 6 weeks.

Who may be able to join

  • > 18 years old
  • Listed for Liver Transplant for ESLD and Kidney Transplant (not on dialysis at time of transplant surgery)
  • Candidates with two native kidneys.
  • Willing to participate and sign informed consent form.

Who cannot join

  • Unstable patients (e.g. in the ICU or those who are on Continuous Renal Replacement Therapy (CRRT) who cannot complete the nuclear medicine scan or those with AKI on Hemodialysis
  • Prior history of any solid organ transplant.
  • Those who are currently pregnant or breast feeding.
  • Patients who have Autosomal Dominant polycystic kidney disease

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Mary Balmes-Fenwick, B.S. contact

317-948-7772

mbalmes@iu.edu

United States1 site, 1 recruiting
  • IU Health University Hospital

    Indianapolis, Indiana, 46202

    Muhammad Y Jan

    Recruiting

Other trials in United States

About this study

Official title: Simultaneous Prospective Kidney Transplant Assessment in Combined Liver Kidney

The purpose of the study is to determine how much a persons kidney function recovers after receiving a simultaneous liver kidney transplant. The investigators will be contacting patients with kidney dysfunction with estimated GFR between 25 and 40 (not on dialysis treatment) who are listed to receive a simultaneous liver kidney (SLK) transplant to look at this function recovery. The investigators hope to develop a criteria based on GFR measurement, kidney function calculations from native kidneys vs transplanted kidney and compare the contributions, and correlate with estimated GFR on basic metabolic panel (BMP: a blood test) to predict higher chances of recovery of native kidney function.

Read the detailed description

Study design

Study will be a pilot longitudinal prospective study. SLK transplant listed patients will be recruited from the outpatient Liver Kidney Transplant Clinic at Medical Diagnostic Clinic (MDC) as well as inpatients admitted to IU University Hospital. Listing status for SLK transplant will be confirmed and patients will be scheduled for a Mag3 nuclear medicine scan at IU University Department of Nuclear medicine. For study purposes, this scan will be done pre and post-transplant to compare the results.

Methods:

Inclusion/Exclusion criteria:

Inclusion:

  1. > 18 years old
  2. Listed for Liver Transplant for ESLD and Kidney Transplant based on eGFR ranging from ≥ 25 to ≤40 mL/min/1.73m2 (not on dialysis at time of surgery)
  3. Candidates with two native kidneys.
  4. Willing to participate and sign informed consent form.

Exclusion Criteria:

  1. Unstable patients (e.g. in the ICU or those who are on Continous Renal Replacement Therapy (CRRT) who cannot complete the nuclear medicine scan or those on Hemodialysis
  2. Prior history of any solid organ transplant.
  3. Those who are currently pregnant or breast feeding.
  4. Patients with a history of Adult Polycystic Kidney Disease

Data collection: Data collection will be done in RedCap©️ These data forms will incorporate a comprehensive list of variables:

  1. Participants demographics and BMI
  2. Reason for ESLD and complications listed in Medical Chart
  3. Medication list
  4. Results of Nuclear medicine scan, eGFR on Basic Metabolic Panel, measurement of eGFR by Cystatin C, 24 hour urinary creatinine clearance and measurement of urinary NGAL level. Radiographically: kidney size, presence of findings such as cysts, stones etc.
  5. Post SLK transplant complications including need for Dialysis, delayed graft function, episodes of rejection, infections and any reason for admission to the hospital
  6. Adherent to Immunosuppression regimen, and type of Immunosuppression regimen
  7. BP readings at follow up clinic visits
  8. Any post SLK transplant imaging for kidney size and any findings (if any imaging is performed for any other indication, none will done for the research study).

Participants will be informed about the results of their studies. Participation will be voluntary. Compensation will be provided once in the form of $25 gift card that will be provided upon completing participation for the nuclear medicine scan 10 months after patients receive their SLK transplant. Patients and their insurance will not be charged and the testing will be invoiced to the study grant.

Provisions for post-study care No provision will be provided for care regarding incidental findings on the nuclear medicine scan. They will be given information regarding referral to seeking appropriate care. No expenses will be reimbursed for this care.

Participant timeline:

Enrollment of participants will be done starting February 2023 and completed by December 2023

Statistical Analyses:

Sample size:

Estimated number of participants is determined by participants listed for SLK transplant. An estimated 15 participants are planned to be recruited. As this is a pilot study, all participants at IU will be asked to participate with a future goal of a multi-center study.

Plans for assessment and collection of outcomes:

Data will be collected in IU RedCap registry, which is a secure platform. Data will be entered in Redcap, coded, secured, and stored. Any raw data collection (source documents) will be kept in a locked cabinet in a locked office. Data will be processed with SPSS data management software.

Confidentiality Information about potential and enrolled participants will be collected, shared, and maintained in a manner that protects confidentiality before, during, and after the study.

Conditions
Transplant
Being tested
Nuclear Medicine Scan
Keywords
Liver, Kidney

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nuclear Medicine ScanRadiation

    Mercaptoacetyltriglycine 3 (Mag 3) Nuclear Medicine Scan

Study groups in NCT05717842
Study groupRoleWhat they receive
People with ESLD and eGFR between >=25 and <=40ml/min1. > 18 years old 2. Listed for Liver Transplant for ESLD and Kidney Transplant (not on dialysis) 3. Candidates with two native kidneys. 4. Willing to participate and sign informed consent
Receives: Radiation: Nuclear Medicine Scan

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. perform a nuclear medicine scan prior to SLK transplant

    To determine split kidney function with a Mag3 (Mercaptoacetyltriglycine 3) nuclear medicine renal scan as part of the study procedures.

    Measured: up to 100 weeks

Secondary outcomes (1)
  1. To measure and correlate Clinical, laboratory and Radiographic data at the time of SLK transplant will be reviewed

    This includes standard testing performed at our center prior to SLK transplant which are standard of care. This will include measurement of eGFR by Cystatin C.

    Measured: up to 100 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Feb 2023
  2. Study start8 Dec 2023
  3. Primary completionDec 2026 (estimated)
  4. Study completionFeb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05717842
Sponsor's protocol ID
15853
Acronym
RECOVERY
Status last verified
Mar 2026
First submitted
2 Dec 2022
Last updated
12 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Transplant, run by Indiana University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Mary Balmes-Fenwick, B.S. (317-948-7772, mbalmes@iu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

perform a nuclear medicine scan prior to SLK transplant (time frame: up to 100 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in